Loading…
Nubratori, Inc. dba Nubratori Rx, a registered outsourcing facility for compounding sterile drugs, was cited for serious deficiencies in drug manufacturing practices that put patients at risk. During a July 2024 FDA inspection, investigators identified violations of current good manufacturing practices and other applicable provisions of the Federal Food, Drug, and Cosmetic Act, resulting in the production of adulterated drug products. The company received a Form FDA 483 and submitted responses in August and October 2024, but the deficiencies were deemed sufficiently serious to warrant a Warning Letter.